CSL112 (Apolipoprotein A-I (Human)) Infusion in Post Myocardial Infarction Patients Promotes Hepatocyte Cholesterol Uptake Ex Vivo

被引：0
|
作者：
Velkoska, Elena
Greene, Brandon
Collins, Heidi L.
Adelman, Steven
Mears, Jenny
Duffy, Danielle
Gibson, C. Michael
Diditchenko, Svetlana
Kingwell, Bronwyn A.
机构：
来源：
CIRCULATION | 2022年 / 146卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A11305
引用
收藏
页数：2
相关论文
共 36 条
  • [1] Infusion of human apolipoprotein A-I (CSL112) promotes several aspects of reverse cholesterol transport
    Mathias, Rommel
    Velkoska, Elena
    Diditchenko, Svetlana
    Greene, Brandon
    Tan, Xiahui
    Navdaev, Alexey
    Collins, Heidi
    Adelman, Steven
    Young, Kyal
    Gille, Andreas
    Duffy, Danielle
    Gibson, Michael
    Pelzing, Matthias
    Kingwell, Bronwyn
    CIRCULATION, 2024, 150
  • [2] CSL112 (human apolipoprotein A-I) infusion rapidly increases apoA-I exchange rate (AER) when administered to patients post myocardial infarction
    Kingwell, B. A.
    Velkoska, E.
    Diditchenko, S.
    Greene, B. H.
    Wang, S.
    Mears, J.
    Wright, S. D.
    Gibson, C. M.
    Smith, J. D.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1212 - 1212
  • [3] Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients
    Zheng, Bo
    Duffy, Danielle
    Tricoci, Pierluigi
    Kastrissios, Helen
    Pfister, Marc
    Wright, Samuel D.
    Gille, Andreas
    Tortorici, Michael A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2558 - 2571
  • [4] Biological Basis and Proposed Mechanism of Action of CSL112 (Apolipoprotein A-I [Human]) for Prevention of Major Adverse Cardiovascular Events in Patients post Myocardial Infarction
    Kazmi, Syed Hassan A.
    Korjian, Serge
    Chi, Gerald
    Kalayci, Arzu
    Lee, Jane J.
    Talib, Usama
    Wright, Samuel D.
    Duffy, Danielle
    Kingwell, Bronwyn A.
    Mehran, Roxana
    Ridker, Paul M.
    AMERICAN HEART JOURNAL, 2021, 242 : 158 - 158
  • [5] CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction
    Kingwell, Bronwyn A.
    Duffy, Danielle
    Clementi, Regina
    Velkoska, Elena
    Feaster, John
    Gibson, C. Michael
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (09):
  • [6] Infusion of CSL112, a novel formulation of human apolipoprotein A-I, in healthy subjects removes tissue cholesterol and directs its clearance
    Gille, A.
    Wright, S.
    Easton, R.
    Shear, C.
    EUROPEAN HEART JOURNAL, 2013, 34 : 350 - 350
  • [7] THE EFFECT OF CSL112 (APOLIPOPROTEIN A-I, HUMAN) ON CHOLESTEROL EFFLUX CAPACITY: A CROSS-STUDY COMPARISON
    Zheng, Bo
    Goto, Shinya
    Clementi, Regina
    Feaster, John
    Duffy, Danielle
    Dalitz, Penelope
    Airey, Jolanta
    Roberts, John
    Korjian, Serge
    Gibson, Michael C.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1026 - 1026
  • [8] CSL112 (apolipoprotein A-I [human]) reduces the elevation in neutrophil-lymphocyte ratio (NLR) induced by acute myocardial infarction
    Kingwell, B.
    Duffy, D.
    Clementi, R.
    Velkoska, E.
    Feaster, J.
    Gibson, C. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [9] CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
    Gille, Andreas
    D'Andrea, Denise
    Tortorici, Michael A.
    Hartel, Gunter
    Wright, Samuel D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (04) : 953 - 963
  • [10] Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
    Korjian, Serge
    Kazmi, Syed Hassan A.
    Chi, Gerald
    Kalayci, Arzu
    Lee, Jane J.
    Talib, Usama
    Wright, Samuel D.
    Duffy, Danielle
    Kingwell, Bronwyn A.
    Mehran, Roxana
    Ridker, Paul M.
    Gibson, C. Michael
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 387 - 398
1234